Baird lowered the firm’s price target on Tandem Diabetes (TNDM) to $24 from $33 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where it appears to be a good start to the year albeit off lowered expectations.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $59 from $58 at Canaccord
- Tandem Diabetes Care: Strong Performance, Promising Outlook, and Buy Rating Affirmed by William Plovanic
- Tandem Diabetes price target lowered to $30 from $36 at Piper Sandler
- Tandem Diabetes price target lowered to $20 from $22 at Wells Fargo
- Tandem Diabetes Care: Strong Q1 Performance Amid Cautious Outlook and Hold Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue